Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine

First real-world comparison shows lower hospitalization and severe illness rates with infant immunization vs maternal vaccination.

By
Andrea Surnit
April 24, 2026
3 min

Conexiant

At a Glance

Category	Detail
Condition	Respiratory syncytial virus (RSV) infection in infants
Key Mechanisms	Nirsevimab provides direct infant immunization shortly after birth; maternal vaccination with RSVpreF vaccine provides passive immunity via maternal antibodies during pregnancy
Target Population	Newborn infants during the RSV season
Care Setting	Pediatric hospital and outpatient settings during RSV season

Key Highlights

Nirsevimab was associated with a 26% lower risk of hospitalization for RSV-associated lower respiratory tract infection compared to maternal RSVpreF vaccination.
Severe RSV outcomes including PICU admission, ventilatory support, and oxygen therapy were less frequent in infants receiving nirsevimab.
The relative benefit of nirsevimab increased over time, with lower hospitalization risk observed beyond 30 and 60 days after discharge.

Guideline-Based Recommendations

Diagnosis

Monitor infants for signs of RSV-associated lower respiratory tract infection during RSV season.

Management

Consider nirsevimab administration shortly after birth for direct infant protection against RSV.
Maternal RSVpreF vaccination during 32 to 36 weeks’ gestation is an alternative strategy for infant protection.

Monitoring & Follow-up

Follow infants post-discharge for hospitalization risk, especially during the first 60 days of life.
Observe for severe RSV outcomes such as need for PICU admission and respiratory support.

Risks

Higher hospitalization risk in the first week post-discharge observed with nirsevimab, likely due to timing of protection onset.
Residual confounding and limited follow-up duration in observational data should be considered.

Patient & Prescribing Data

Newborn infants during the 2024-2025 RSV season in France

Nirsevimab provides earlier and sustained protection against RSV hospitalization and severe outcomes compared to maternal vaccination; both strategies reduce adverse RSV-related events.

Clinical Best Practices

Match patient characteristics such as gestational age, sex, and region when evaluating RSV prevention strategies.
Consider timing of immunization relative to birth and RSV season to optimize protection.
Use both direct infant immunization and maternal vaccination approaches as complementary strategies depending on clinical context.
Interpret observational study findings with caution due to potential residual confounding and limited generalizability.